

Axio BioPharma Selects Ansa Biotechnologies as Preferred Gene Synthesis Provider

Preferred partnership helps strengthen high-throughput antibody production workflows by reducing schedule risk and improving delivery predictability

MADISON, WI, UNITED STATES, August 24, 2026 /EINPresswire.com/ -- [Axio BioPharma](#), a vendor-neutral data infrastructure company for biomanufacturing, today named [Ansa Biotechnologies](#), the trusted partner in DNA synthesis, as its preferred gene

synthesis provider. Axio Forge, the company's high-throughput non-GMP monoclonal antibody laboratory, already routes gene synthesis to Ansa across its production workflows. Forge delivers purified antibodies on a 3-5 week turnaround from electronic sequence, with a fee-for-service model.

Gene synthesis is the first step in every antibody production program, so a delay there holds back every downstream activity, from expression and purification through characterization and delivery. Routing that work to Ansa removes one of the earliest sources of schedule risk in the Forge workflow.

Ansa's proprietary synthesis platform provides the length, complexity, and scalability required to design and manufacture even the most demanding DNA constructs. The Ansa On-Time Guarantee ensures complete orders are shipped by the committed date or they are free of charge. Manufactured exclusively in the United States, Ansa's products integrate seamlessly into existing workflows to accelerate the next wave of biological discovery. Ansa operates under a rigorous biosecurity framework and is fully compliant with the U.S. Office of Science and Technology Policy [Framework for Nucleic Acid Synthesis Screening](#).

"Customers don't measure success by how quickly we can move on our best day. They measure it by whether we deliver when we said we would," said Justin Byers, Founder and Chief Executive Officer of Axio BioPharma. "Gene synthesis is one of the earliest steps in antibody production, but it often determines whether an entire program stays on schedule. Working with Ansa gives



us greater confidence that the timelines we commit to our customers are timelines we can consistently deliver, including for the complex constructs that have traditionally created the greatest uncertainty."

The collaboration reflects Axio BioPharma's broader strategy of building an ecosystem of specialized technology partners that improve consistency, reduce operational variability, and support more predictable biologics development from molecular design through laboratory execution.

"Reliable gene synthesis is foundational to accelerating biologics development," said Jason T. Gammack, Chief Executive Officer of Ansa Biotechnologies. "Our mission is to eliminate uncertainty at one of the earliest stages of the workflow so researchers can move forward with confidence. We're proud to support Axio BioPharma and its Forge platform as they continue helping customers bring antibody programs from sequence to purified material with greater speed and predictability."

As demand for faster biologics development continues to increase, partnerships that strengthen critical upstream workflows are becoming increasingly important. By combining Axio Forge's high-throughput antibody production capabilities with Ansa's enzymatic DNA synthesis technology, the companies are helping to provide researchers with a more reliable foundation for antibody discovery while reducing one of the most common sources of schedule risk early in development.

About Axio BioPharma

Axio BioPharma is a vendor-neutral data infrastructure company for biomanufacturing. Axio Lattice is a coordination and translation layer that lets pharma sponsors and their manufacturing partners work from the same process data across organizational boundaries, without moving data or changing ownership. Axio Forge is a high-throughput non-GMP antibody lab producing research-grade monoclonal antibodies on a 3-5 week turnaround. Axio is headquartered in Madison, Wisconsin.

Learn more at www.axiobiopharma.com.

Media Contact

Madelyn De Los Santos
Putnam Insights
madelyn@putnaminsights.com

This press release can be viewed online at: <https://www.einpresswire.com/article/934239354>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.